- The "canary" in the AI market is still struggling...
- Spanish government bond auction sees strong demand, yields rise across all four maturities, with 5-year yield surpassing 3%
- U.S. Department of Energy: Oklo's small nuclear reactor has achieved "critical" status.
- Japanese Yen: Retail flows reshape post-intervention dynamics – MUFG
- Violent crypto attacks surge in 2026 with over $124M in financial exposure, France hit hardest
- Alphabet (GOOG.US) has begun marketing a US investment-grade bond offering after raising its 2026 capital expenditure forecast, which triggered a selloff in AI-related bonds. The company is now testing investor appetite for its debt financing. According to a person familiar with the matter, Alphabet plans to issue up to 10 tranches of bonds with maturities ranging from 2 to 40 years. The person stated that the initial price guidance for the longest-maturity bonds is about 1.55 percentage points
- Alphabet (GOOG.US) seeks to raise up to 25 billion dollars through a bond issuance. (Bloomberg)
- Ensysce Biosciences posts investor presentation spotlighting trypsin-controlled opioid platforms, pain pipeline
- Valeo reports 245,607,624 issued shares, 272,826,796 exercisable voting rights as of July 31, 2026
- Altron subsidiary director receives performance share award valued at R 9.3 million
- Freshworks Freshservice gains FedRAMP In-Process status for Moderate certification
- Spot platinum has just broken through the $1,740.00/oz mark, last quoted at $1,739.81/oz, up 0.19% on the day; Nymex platinum futures main contract is last quoted at $1,754.4/oz, up 0.43% on the day.
- Prime Medicine publishes corporate presentation on prime editing platform, liver disease pipeline focus
- Barinthus Bio Q2 FY26 net loss widens to $10.6 million
- Regency Centers declares quarterly common dividend of $0.76 a share
- Mink Therapeutics to report Q2 results, host conference call and webcast
- Gogo Q2 2026 turns to net loss of $2 million; revenue slips 2% to $222.8 million vs Q1 2026
- Templeton Emerging Markets Investment Trust answers shareholder questions ahead of AGM
- Largo names James Bannantine co-CEO as Daniel Tellechea retires
- Neogen CEO Nassif Mikheal reports acquisition of 370 common shares worth $4,369.70
- Oklo says Groves isotope test reactor reaches first criticality in Texas
- CRA International says Q2 FY2026 revenue rises to $210.8 million on higher utilization, lower SG&A ratio
- CRA International FY26 Q2 net income rises 11.4% to $13.5 million; revenue climbs 12.8% to $210.8 million
- NetScout Q1 FY2027 revenue rises 13% as government-related Service Assurance orders accelerate, company says
- Montebalito H1 2026 net loss narrows to EUR 900,000; net sales rise 21.97% to EUR 1.36 million
- BRIEF-Nexpoint Real Estate Finance Q2 EPS USD 0.29
- CG Oncology: Cash, Cash Equivalents and Marketable Securities Sufficient to Fund Ops Through 2029 >CGON
- NexPoint Real Estate Fin 2Q EPS 29c >NREF
- Western Digital Corporation Stock Drops 11% Despite Beating Earnings
- Sui crypto sinks to $0.67, stuck below $1.01 EMA200 level
- SHOPIFY INC. <SHOP.O>: WEDBUSH RAISES TARGET PRICE TO $176 FROM $155
- ZILLOW GROUP, INC. <ZG.O>: BERNSTEIN CUTS TO MARKET-PERFORM FROM OUTPERFORM; CUTS TARGET PRICE TO $38 FROM $50
- Banzai International plans rebrand as Parabolic Technologies, ticker to change to PARA
- CRA International expands and extends credit facility to $400 million
- Suncor CEO Rich Kruger to become executive vice chair in 2027, names Peter Zebedee as successor
- EXL President Vikas Bhalla disposes of 11,000 shares for $384,890.99
- CG Oncology 2Q Loss/Shr 90c >CGON
- CG Oncology 2Q Loss $79.1M >CGON
- APPLOVIN CORPORATION : WEDBUSH CUTS TARGET PRICE TO $610 FROM $640
- INSULET CORPORATION : BERNSTEIN CUTS TARGET PRICE TO $175 FROM $200
- FLUTTER ENTERTAINMENT PLC <FLUT.N>: WEDBUSH CUTS TARGET PRICE TO $126 FROM $138
- Bed Bath & Beyond Executive Chairman and CEO Marcus Lemonis acquires common shares worth $202,592.94
- HUBSPOT, INC. <HUBS.N>: BERNSTEIN CUTS TO MARKET-PERFORM FROM OUTPERFORM; CUTS TARGET PRICE TO $220 FROM $381
- DHT forecasts Q3 spot rates booked to date at $152,700 a day for 58% of spot days
- Pasinex launches tender for 500 DMT of 46% zinc sulphide from Pinargozu mine
- CRA International declares quarterly cash dividend of $0.57 per share
- Delcath net income holds at $2.7 million in Q2 FY26; revenue rises 20.25% to $29.1 million vs Q2 FY25
- NetApp acquires VMware disaster recovery firm JetStream Software
- Ascendis Pharma posts COACH Week 78 achondroplasia program update presentation
- Theriva Biologics doses first patient in VIRAGE2 Phase 2a trial of VCN-01 for metastatic pancreatic cancer
- Fox posts fiscal 2026 Q4, full-year earnings release report link
- Principal Asset Management names Daniel Maric head of European distribution
- Ensysce Biosciences completes Cy Biopharma acquisition
- Nano-X Imaging prices USD 8 million registered direct offering at USD 1 per share with warrants
- Sif Holding publishes transcript of Interim Results 2026 webcast
- REVOLUTION MEDICINES, INC. <RVMD.O>: WEDBUSH RAISES TARGET PRICE TO $201 FROM $192.1
- Iovance publishes corporate presentation highlighting Amtagvi TIL therapy rollout and pipeline expansion in solid tumors
- Chegg Q2 FY26 net loss narrows to $3 million; revenue drops 51% to $51.8 million
- Safe Harbor 401(k) plan wins Canopy HR endorsement for cannabis clients
- BlackRock TCP Capital sells $511.9 million investment portfolio in asset transaction
- MBX Biosciences posts corporate presentation on precision peptide programs for endocrine, metabolic diseases
- Fox Q4 FY26 net income slips 3% to $696 million; revenue rises 28% to $4.21 billion
- Oncor Q2 net income rises to $428 million from $259 million
- BRIEF-CRA International Q2 Adjusted EPS USD 2.16
- IMC scales CoreWeave AI cloud use to expand research computing footprint
- Chegg Sees 3Q Rev $43M-$44M >CHGG
- Ralph Lauren Continues to Expect Cap Expenditures for FY27 of About 4% to 5% of Rev >RL
- Prime Medicine 3Q Loss/Shr 24c >PRME
- Prime Medicine 3Q Loss $42.1M >PRME
- Aligos Therapeutics 2Q Loss $1.5M >ALGS
- White Mountains Insurance 2Q Net $199M >WTM
- Whitehawk Therapeutics 2Q Research and Development Expenses $12.9M >WHWK
- Praxis Precision Med 2Q Loss $83.7M >PRAX
- Delcath Systems 2Q Net $2.67M >DCTH
- Ralph Lauren Sees 2Q Revenue Growing About Mid-Single Digits on Constant Currency Basis, Centered Around 5% to 6% >RL
- Delcath Systems 2Q Rev $29.1M >DCTH
- Praxis Precision Med 2Q Loss/Shr $2.87 >PRAX
- LEMAITRE VASCULAR, INC. <LMAT.O>: BARRINGTON RESEARCH RAISES TO OUTPERFORM FROM MARKET PERFORM
- Ascendis Pharma posts slide presentation on achondroplasia program updates
- Kratos wins US Army contract to develop next-generation infrared seeker for Javelin missile system
- BRIEF-Chegg Q2 Revenue USD 51.849 Million
- Centrus Energy signs LEU, HALEU enrichment supply deal with X-energy
- vTv Therapeutics Q2 FY26 net loss widens to $13.1 million; R&D expenses more than doubled to $8.8 million
- BlackRock TCP Capital Q2 FY26 net investment income falls to $18.14 million; revenue drops to $40 million
- Hyliion wins USD 41.7 million U.S. Navy contract for multi-megawatt KARNO power modules
- Rallybio swings to Q2 net income of $43.67 million; operating loss narrows to $5.65 million
- SHOPIFY INC. <SHOP.TO>: ATB CORMARK CAPITAL MARKETS RAISES TARGET PRICE TO C$260 FROM C$240
- USA TODAY 2Q Rev $536.3M >TDAY
- Hertz Global 2Q Adj Loss/Shr 11c >HTZ
- vTv Therapeutics 2Q Loss/Shr $1.05 >VTVT
- Hertz Global 2Q Rev $2.4B >HTZ
- Acorn Energy 2Q Rev $2.49M >ACFN
- Acorn Energy 2Q EPS 12c >ACFN
- New spot margin trading pair — QUID/USDT!
- New spot margin trading pair — US/USDT!
- EPAM Systems Sees FY EPS $8.22-EPS $8.38 >EPAM
- EPAM Systems 2Q EPS $1.97 >EPAM
- EPAM Systems 2Q Adj EPS $3.38 >EPAM
- EPAM Systems Sees 3Q Adj EPS $3.38-Adj EPS $3.46 >EPAM
- EPAM Systems Sees 3Q EPS $2.33-EPS $2.41 >EPAM
